Technical Papers

750 Results

Quatrefolic®: The Active folate vs Folic Acid

Quatrefolic®: The Active folate vs Folic Acid

Gnosis by Lesaffre USA | 31-Aug-2021 | Infographic

Folate deficiency concerns everyone at every step of their life. The supplementation of vitamin B9 is often be misunderstood, especially regarding the...

Actilight® and infant nutrition: new perspectives

Actilight® and infant nutrition: new perspectives

Tereos | 31-Aug-2021 | Technical / White Paper

Addition of prebiotic ingredients to formulas started around 30 years ago and is widely recognized by experts. Actilight® scFOS is safe for use in infant...

It’s time to redefine mobility

It’s time to redefine mobility

BIOIBERICA, S.A.U. | 12-Jul-2021 | Insight Guide

At Bioiberica, we’re tapping into the demand for holistic health solutions with a new identity for our Healthcare branded ingredients – starting with mobility....

How to Enter UK’s £690M CBD Market

How to Enter UK’s £690M CBD Market

The Association for the Cannabinoid Industry | 18-Jun-2021 | Technical / White Paper

The UK has the world’s most developed regulatory framework for legal cannabinoids, such as CBD and CBG. With a 2021 market estimated to be worth £690 million...

I am vaccinated, what´s next?

I am vaccinated, what´s next?

Biosearch Life | 16-Jun-2021 | Infographic

The COVID-19 pandemic has led to a lot of questions around how the immune system works and how to support it with nutrition. While vaccines work by driving...

Your bioavailable and soluble anti-aging curcumin

Your bioavailable and soluble anti-aging curcumin

Lipofoods, a Lubrizol Company | 11-Jun-2021 | Technical / White Paper

Curcumin´s antioxidant and anti-inflammatory potential is limited by its poor solubility and its low bioavailability. In this respect, Lubrizol microencapsulated...

Business case: private label iron supplements

Business case: private label iron supplements

PharmaLinea Ltd. | 18-May-2021 | Case Study

A line of clinically supported private label iron supplements by PharmaLinea is selling nearly 500.000 units/year in a market of under 20 million people.

REVOLUTIONARY PRODUCT for CHRONIC KIDNEY DISEASE

REVOLUTIONARY PRODUCT for CHRONIC KIDNEY DISEASE

THINQ Pharma-CRO Pte Ltd | 17-May-2021 | Clinical Study

IS THERE AN ORALLY CONSUMABLE PRODUCT USEFUL FOR DECREASING SERUM CREATININE LEVEL, DECREASE IN BLOOD UREA NITROGEN, INCREASING eGLOMARULAR FILTRATION...

DailyZz™ - Wake-up to the difference

DailyZz™ - Wake-up to the difference

Kemin Health Europe | 06-May-2021 | Data Sheet

Did you know that more than half of European consumers are unsatisfied with the daily amount of sleep and sleep quality? Quality sleep is essential for...

Follow us

Products

View more

Webinars